BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27685104)

  • 21. Dosimetric optimization of a colpostat in a 60Co high-dose-rate brachytherapy unit for bladder sparing.
    Zakariaee SS; Mahdavi SR
    Brachytherapy; 2015; 14(1):37-45. PubMed ID: 25260688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organ-specific radiation-induced cancer risk estimates due to radiotherapy for benign pigmented villonodular synovitis.
    Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
    Phys Med Biol; 2016 Sep; 61(17):6400-12. PubMed ID: 27499236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OUT-OF-FIELD DOSES IN CHILDREN TREATED FOR LARGE ARTERIOVENOUS MALFORMATIONS USING HYPOFRACTIONATED GAMMA KNIFE RADIOSURGERY AND INTENSITY-MODULATED RADIATION THERAPY.
    De Saint-Hubert M; Majer M; Hršak H; Heinrich Z; Kneževic Ž; Miljanic S; Porwol P; Stolarczyk L; Vanhavere F; Harrison RM
    Radiat Prot Dosimetry; 2018 Oct; 181(2):100-110. PubMed ID: 29351691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Out-of-field doses from secondary radiation produced in proton therapy and the associated risk of radiation-induced cancer from a brain tumor treatment.
    Ardenfors O; Dasu A; Lillhök J; Persson L; Gudowska I
    Phys Med; 2018 Sep; 53():129-136. PubMed ID: 30241747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical evaluation of secondary cancer risk models applied to Monte Carlo dose distributions of 2-dimensional, 3-dimensional conformal and hybrid intensity-modulated radiation therapy for breast cancer.
    Joosten A; Bochud F; Moeckli R
    Phys Med Biol; 2014 Aug; 59(16):4697-722. PubMed ID: 25082795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
    Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
    Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doses to internal organs for various breast radiation techniques--implications on the risk of secondary cancers and cardiomyopathy.
    Pignol JP; Keller BM; Ravi A
    Radiat Oncol; 2011 Jan; 6():5. PubMed ID: 21235766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of surface and shallow depth dose reductions using a Superflab bolus during conventional and advanced external beam radiotherapy.
    Yoon J; Xie Y; Zhang R
    J Appl Clin Med Phys; 2018 Mar; 19(2):137-143. PubMed ID: 29427312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between beta radiation dose distribution due to LDR and HDR ocular brachytherapy applicators using GATE Monte Carlo platform.
    Mostafa L; Rachid K; Ahmed SM
    Phys Med; 2016 Aug; 32(8):1007-18. PubMed ID: 27499370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of organ doses in brachytherapy treatment of uterus cancer using mathematical reference Indian adult phantom.
    Biju K
    Radiat Prot Dosimetry; 2012 Jan; 148(2):185-8. PubMed ID: 21343234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of organ doses for patients undergoing balloon brachytherapy of the breast with HDR 192Ir or electronic sources using monte carlo simulations in a heterogeneous human phantom.
    Mille MM; Xu XG; Rivard MJ
    Med Phys; 2010 Feb; 37(2):662-71. PubMed ID: 20229875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calculating and estimating second cancer risk from breast radiotherapy using Monte Carlo code with internal body scatter for each out-of-field organ.
    Takata T; Shiraishi K; Kumagai S; Arai N; Kobayashi T; Oba H; Okamoto T; Kotoku J
    J Appl Clin Med Phys; 2020 Dec; 21(12):62-73. PubMed ID: 33128332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of planned and measured rectal dose in-vivo during high dose rate Cobalt-60 brachytherapy of cervical cancer.
    Zaman ZK; Ung NM; Malik RA; Ho GF; Phua VC; Jamalludin Z; Baharuldin MT; Ng KH
    Phys Med; 2014 Dec; 30(8):980-4. PubMed ID: 25086486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of various approaches for assessing dose indicators and patient organ doses resulting from radiotherapy cone-beam CT.
    Rampado O; Giglioli FR; Rossetti V; Fiandra C; Ragona R; Ropolo R
    Med Phys; 2016 May; 43(5):2515. PubMed ID: 27147362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Image-guided cervix high-dose-rate brachytherapy treatment planning: does custom computed tomography planning for each insertion provide better conformal avoidance of organs at risk?
    Davidson MT; Yuen J; D'Souza DP; Batchelar DL
    Brachytherapy; 2008; 7(1):37-42. PubMed ID: 18299111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of grid size on uniform scanning and IMPT plans in XiO treatment planning system for brain cancer.
    Rana S; Zheng Y
    J Appl Clin Med Phys; 2015 Sep; 16(5):447–456. PubMed ID: 26699310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorbed dose calculations in a brachytherapy pelvic phantom using the Monte Carlo method.
    Rodríguez ML; deAlmeida CE
    J Appl Clin Med Phys; 2002; 3(4):285-92. PubMed ID: 12383048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calculated organ doses from selected prostate treatment plans using Monte Carlo simulations and an anatomically realistic computational phantom.
    Bednarz B; Hancox C; Xu XG
    Phys Med Biol; 2009 Sep; 54(17):5271-86. PubMed ID: 19671968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiobiologic comparison of helical tomotherapy, intensity modulated radiotherapy, and conformal radiotherapy in treating lung cancer accounting for secondary malignancy risks.
    Komisopoulos G; Mavroidis P; Rodriguez S; Stathakis S; Papanikolaou N; Nikiforidis GC; Sakellaropoulos GC
    Med Dosim; 2014; 39(4):337-47. PubMed ID: 25168596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.